Skip to main content
. 2020 Sep 2;70(10):484–488. doi: 10.1055/a-1236-3041

Fig. 1.

Fig. 1

A summary of the probable mechanisms by which proton pump inhibitors (PPIs) could impart therapeutic benefits in COVID-19. While most of the hypothesized mechanisms and in silico findings support their inclusion as potential candidates for repurposing against SARS-CoV-2, clinical evidences do not point towards any benefit unambiguously, denying us from arriving at a definite conclusion.